Cancer metastasis
Johnson & Johnson Announces Promising Results for Amivantamab in Head and Neck Cancer Study
The European Society for Medical Oncology (ESMO) 2025 Congress saw the presentation of data from the Phase 1b/2 OrigAMI-4 study evaluating the efficacy and safety of subcutaneous amivantamab monotherapy in patients with human papillomavirus (HPV)-unrelated, recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) after